Literature DB >> 12819040

Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways.

Piet Finckenberg1, Kaija Inkinen, Juhani Ahonen, Saara Merasto, Marjut Louhelainen, Heikki Vapaatalo, Dominik Müller, Detlev Ganten, Friedrich Luft, Eero Mervaala.   

Abstract

Connective tissue growth factor (CTGF) is a polypeptide implicated in the extracellular matrix synthesis. Previous studies have provided evidence that angiotensin II (Ang II) promotes collagen synthesis and regulates collagen degradation. We investigated whether or not CTGF mediates the profibrotic effects of Ang II in the heart and kidneys and the role of calcineurin-dependent pathways in CTGF gene regulation. In transgenic rats harboring human renin and angiotensinogen genes, Ang II induced an age-dependent increase in myocardial CTGF expression, which was 3.5-fold greater compared to normotensive Sprague Dawley (SD) rats. CTGF overexpression correlated closely with the Ang II-induced rise in blood pressure. CTGF mRNA and protein were located predominantly in areas with leukocyte infiltration, myocardial, and vascular lesions and co-localized with TGFbeta(1), collagen I, and collagen III mRNA expressions. Ang II induced CTGF mRNA and protein to a lesser extent in the kidneys, predominantly in glomeruli, arterioles, and in the interstitium with ample inflammation. However, no expression was found in the right ventricle or pulmonary arteries. Blockade of calcineurin activity by cyclosporine A completely normalized Ang II-induced CTGF overexpression in heart and kidney, suppressed the inflammatory response, and mitigated Ang II-induced cell proliferation and apoptosis. In contrast, blockade of mTOR (target of rapamycin) pathway by everolimus, further increased the expression of CTGF even though everolimus ameliorated cell proliferation and T-cell-mediated inflammation. Our findings provide evidence that CTGF mediates Ang II-induced fibrosis in the heart and kidneys via blood pressure and calcineurin-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819040      PMCID: PMC1868168          DOI: 10.1016/S0002-9440(10)63659-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.

Authors:  E Mervaala; D N Müller; J K Park; R Dechend; F Schmidt; A Fiebeler; M Bieringer; V Breu; D Ganten; H Haller; F C Luft
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

2.  Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative.

Authors:  C Daniel; R Ziswiler; B Frey; M Pfister; H P Marti
Journal:  Exp Nephrol       Date:  2000 Jan-Feb

3.  NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats.

Authors:  D N Muller; R Dechend; E M Mervaala; J K Park; F Schmidt; A Fiebeler; J Theuer; V Breu; D Ganten; H Haller; F C Luft
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model.

Authors:  J Bohlender; S Gerbaulet; J Krämer; M Gross; M Kirchengast; R Dietz
Journal:  Hypertension       Date:  2000-04       Impact factor: 10.190

5.  Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts.

Authors:  R C Pereira; D Durant; E Canalis
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-09       Impact factor: 4.310

6.  Blood pressure-independent effects in rats with human renin and angiotensinogen genes.

Authors:  E Mervaala; D N Müller; F Schmidt; J K Park; V Gross; M Bader; V Breu; D Ganten; H Haller; F C Luft
Journal:  Hypertension       Date:  2000-02       Impact factor: 10.190

7.  Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.

Authors:  D N Müller; E M Mervaala; R Dechend; A Fiebeler; J K Park; F Schmidt; J Theuer; V Breu; N Mackman; T Luther; W Schneider; D Gulba; D Ganten; H Haller; F C Luft
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 8.  NAD(P)H oxidase: role in cardiovascular biology and disease.

Authors:  K K Griendling; D Sorescu; M Ushio-Fukai
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

9.  Regulation of connective tissue growth factor expression by prostaglandin E(2).

Authors:  D A Ricupero; D C Rishikof; P P Kuang; C F Poliks; R H Goldstein
Journal:  Am J Physiol       Date:  1999-12

10.  Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes.

Authors:  H Ito; Y Hirata; S Adachi; M Tanaka; M Tsujino; A Koike; A Nogami; F Murumo; M Hiroe
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more
  26 in total

1.  Harbingers of hypertrophy and heart failure.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 2.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 3.  CCN2, the connective tissue growth factor.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2008-01       Impact factor: 4.599

4.  Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.

Authors:  Aleksey Nakorchevsky; Johannes A Hewel; Sunil M Kurian; Tony S Mondala; Daniel Campbell; Steve R Head; Christopher L Marsh; John R Yates; Daniel R Salomon
Journal:  J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 10.121

Review 5.  Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 6.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

7.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

8.  mTOR Complexes Repress Hypertrophic Agonist-Stimulated Expression of Connective Tissue Growth Factor in Adult Cardiac Muscle Cells.

Authors:  Kamala Sundararaj; Dorea L Pleasant; Phillip C Moschella; Kavin Panneerselvam; Sundaravadivel Balasubramanian; Dhandapani Kuppuswamy
Journal:  J Cardiovasc Pharmacol       Date:  2016-02       Impact factor: 3.105

9.  Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes.

Authors:  T Bäcklund; E Palojoki; A Saraste; A Eriksson; P Finckenberg; V Kytö; P Lakkisto; E Mervaala; L-M Voipio-Pulkki; M Laine; I Tikkanen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

10.  Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat.

Authors:  Erik Vahtola; Marjut Louhelainen; Hanna Forstén; Saara Merasto; Johanna Raivio; Petri Kaheinen; Ville Kytö; Ilkka Tikkanen; Jouko Levijoki; Eero Mervaala
Journal:  Cardiovasc Diabetol       Date:  2010-01-27       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.